ERBB3 and cancer: Conversely, TRβ-T3 decreased levels of receptor tyrosine kinases ERBB3 (HER3), FGFR3, and FGFR4. This impact on PI3K pathway attenuation resulted in increased sensitivity to the PI3K inhibitors LY294002 and buparlisib, providing a provocative implication on the relationship between TRβ status in cancer patients and response to therapies.